Between 2016 and 2022, the rate of US adults with type 2 diabetes who used glucagon-like peptide-1 (GLP-1) receptor agonists rose from about 4% to nearly 20%, according to the Medical Expenditure Panel Survey Household Component. Now, new data from the Centers for Disease Control and Prevention reveal that almost 27% of adults diagnosed with diabetes used injectable GLP-1 drugs in 2024, often while taking some other diabetes medication.